Difference between revisions of "Pediatric-type diffuse low-grade glioma"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) (New WHO category 2021) |
Jensflorian (talk | contribs) (MAPK-altered entity added) |
||
Line 16: | Line 16: | ||
=Diffuse low-grade glioma, MAPK pathway-altered= | =Diffuse low-grade glioma, MAPK pathway-altered= | ||
* Since 2021 official WHO entity. | |||
* Astrocytic or oligodendroglial morphology. | |||
* Mostly in the cerebral hemispheres. | |||
* Commonly associated with epilepsy. | |||
* Olig2-ve, GFAP variable, CD34 mostly absent. | |||
* IDH and HF3FA mutations and CDKN2A deletions not compatible with this diagnosis. | |||
* Mutations in BRAF (V600E), FGFR1 or duplication in FGFR1 TKD. |
Revision as of 09:48, 5 April 2022
The category Pediatric-type diffuse low-grade glioma contains diffusely-growing brain tumours with specific molecular alterations belonging into the main group of Glioma. This category consists of mostly CNS WHO grade 1 tumors, observed in children and young-adults.
The fifth edition of CNS WHO classfication recognizes four distinct tumour diagnoses.
- Diffuse astrocytoma, MYB- or MYBL-altered.
- Angiocentric glioma.
- Polymorphous low-grade tumor of the young (PLNTY).
- Diffuse low-grade glioma, MAPK pathway-altered.
Polymorphous low-grade tumor of the young (PLNTY)
- Since 2021 official WHO entity.
- Abbreviated PLNTY.
- Epilepsy-associated.
- Oligodendroglioma-like histologic features.
- Frequently CD34+ve.[1]
- FGFR3-TACC3 and FGFR2-CTNNA3 fusions.
Diffuse low-grade glioma, MAPK pathway-altered
- Since 2021 official WHO entity.
- Astrocytic or oligodendroglial morphology.
- Mostly in the cerebral hemispheres.
- Commonly associated with epilepsy.
- Olig2-ve, GFAP variable, CD34 mostly absent.
- IDH and HF3FA mutations and CDKN2A deletions not compatible with this diagnosis.
- Mutations in BRAF (V600E), FGFR1 or duplication in FGFR1 TKD.
- ↑ Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK (March 2017). "Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway". Acta Neuropathol 133 (3): 417–429. doi:10.1007/s00401-016-1639-9. PMC 5325850. PMID 27812792. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325850/.